protein-dynamics
(2)
MOMA Therapeutics
MOMA Therapeutics is a Cambridge, Massachusetts biotech building precision small-molecule medicines against 'molecular machines' - the highly dynamic, shape-shifting enzymes (ATPases, GTPases and related proteins) that power cellular processes and underlie cancer and other diseases. Spun out of Third Rock Ventures in 2020 by four academic leaders in protein biophysics and structural biology, MOMA's proprietary KNOMATIC platform fuses deep structural insight, advanced hit-finding (fragment and DNA-encoded library screening) and machine-learning-driven lead optimization to drug targets long considered intractable. The company has raised about $236M, advanced its first oncology program into the clinic, and partnered with Roche and Bayer.
Fathom Therapeutics
Fathom Therapeutics (formerly Atommap) is a New York and Boston based biotech building Microcosmos, a drug-design engine that fuses quantum chemistry and AI to simulate how proteins actually move inside living cells. By modeling motion instead of static snapshots - reportedly up to 10,000x faster than conventional simulation - the company hunts for the fleeting binding pockets that make 'undruggable' targets druggable, then designs small molecules, degraders, and molecular glues against them. In April 2026 it raised a $47M oversubscribed Series A led by Sutter Hill Ventures.